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Abstract: Viral hepatitis is a major health problem worldwide, the principal cause of cirrhosis 
and hepatocarcinoma. Once cirrhosis o
hypertension become evident and, sometimes, life threatening for patients. Among the various 
complications of liver cirrhosis, the alteration of haemostatic balance is often a hard challenge 
for  the clinician,  since it is  capable  to predispose  both  to bleeding or thrombosis.  In  this 
review,  we  analyze  the  principal  aspects  of  procoagulant,  anticoagulant  and  fibrinolytic 
capacity of cirrhotic patients, which appears to be variably altered in all these a
only in the direction of a tendency to bleeding. Laboratory investigations, at present, may 
provide only a partial representation of this condition, because of the impossibility to obtain a 
test capable to furnish a global overview of the haemo
conditions. Furthermore, we describe the pathophysiological mechanisms underlying bleeding 
manifestations and thrombosis development in cirrhotic patients,  which should be considered 
not only as obvious consequences of the advanced liver disease but, rat
complex interaction between inherited and acquired factors.
Introduction:  In the  late  1960’s  the  only  known 
pathogens belonging to hepatitis virus fa
hepatitis virus A and B
1, the former spread through 
fecal-oral transmission with short incubation period, 
the  latter  spread  by  blood  contamination  with  a 
longer  incubation  period.  About  ten  years  later, 
blood  samples  from  patients  with  a 
transfusion-associated hepatitis B, were found to be 
negative for both B or A virus infection. That was 
the first identification of “non-A, non
C virus
2. Hepatitis B and C are the most diffused 
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Viral hepatitis is a major health problem worldwide, the principal cause of cirrhosis 
and hepatocarcinoma. Once cirrhosis occurs, the consequences of liver dysfunction and portal 
hypertension become evident and, sometimes, life threatening for patients. Among the various 
complications of liver cirrhosis, the alteration of haemostatic balance is often a hard challenge 
linician,  since it is  capable  to predispose  both  to bleeding or thrombosis.  In  this 
review,  we  analyze  the  principal  aspects  of  procoagulant,  anticoagulant  and  fibrinolytic 
capacity of cirrhotic patients, which appears to be variably altered in all these a
only in the direction of a tendency to bleeding. Laboratory investigations, at present, may 
provide only a partial representation of this condition, because of the impossibility to obtain a 
test capable to furnish a global overview of the haemostatic system and to reproduce 
conditions. Furthermore, we describe the pathophysiological mechanisms underlying bleeding 
manifestations and thrombosis development in cirrhotic patients,  which should be considered 
not only as obvious consequences of the advanced liver disease but, rather, as the result of a 
complex interaction between inherited and acquired factors.
In the  late  1960’s  the  only  known 
pathogens belonging to hepatitis virus family were 
, the former spread through 
oral transmission with short incubation period, 
the  latter  spread  by  blood  contamination  with  a 
longer  incubation  period.  About  ten  years  later, 
blood  samples  from  patients  with  a  suspected 
associated hepatitis B, were found to be 
negative for both B or A virus infection. That was 
A, non-B”, hepatitis 
. Hepatitis B and C are the most diffused 
infections  worldwide  and  the  principal
cirrhosis and hepatocellular carcinoma. About 350 
and 180 million people are affected by hepatitis B 
and C, respectively: viral hepatitis is a major health 
problem, interesting approximatively 3
population
3,4,5,6,7. In low income coun
East Asia and Africa hepatitis B and C are endemic, 
due  to  socioeconomic  conditions;  in  contrast,  in 
industrialized  countries  the  burden  of  hepatitis  B 
and C has been related to the use of infected blood 
products  or  other  iatrogenic  procedur
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Viral hepatitis is a major health problem worldwide, the principal cause of cirrhosis 
ccurs, the consequences of liver dysfunction and portal 
hypertension become evident and, sometimes, life threatening for patients. Among the various 
complications of liver cirrhosis, the alteration of haemostatic balance is often a hard challenge 
linician,  since it is  capable  to predispose  both  to bleeding or thrombosis.  In  this 
review,  we  analyze  the  principal  aspects  of  procoagulant,  anticoagulant  and  fibrinolytic 
capacity of cirrhotic patients, which appears to be variably altered in all these aspects, not 
only in the direction of a tendency to bleeding. Laboratory investigations, at present, may 
provide only a partial representation of this condition, because of the impossibility to obtain a 
static system and to reproduce in vivo
conditions. Furthermore, we describe the pathophysiological mechanisms underlying bleeding 
manifestations and thrombosis development in cirrhotic patients,  which should be considered 
her, as the result of a 
infections  worldwide  and  the  principal cause  of 
cirrhosis and hepatocellular carcinoma. About 350 
and 180 million people are affected by hepatitis B 
and C, respectively: viral hepatitis is a major health 
problem, interesting approximatively 3-6% of world 
. In low income countries of South-
East Asia and Africa hepatitis B and C are endemic, 
due  to  socioeconomic  conditions;  in  contrast,  in 
industrialized  countries  the  burden  of  hepatitis  B 
and C has been related to the use of infected blood 
products  or  other  iatrogenic  procedures,  sexual Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
transmission or drug abuse. Nowadays, prophylaxis 
and  control  of  medical  devices  and  a  specific 
educational policy have strongly downsized the risk 
of  transmission
8.  By  the  way,  about  8-20%  of 
patients  with  chronic  hepatitis  B  develop  liver 
cirrhosis within 5 years, while hepatitis C virus is 
responsible for 40% of cases of endstage cirrhosis 
in industrialized countries
8. Viral cirrhosis, except 
for  some  histological  features,  is  not  clinically 
different from cirrhosis of other origin. Both viral
and  non-viral  cirrhosis  cause  impairment  in 
synthetic,  catabolic and  metabolic  function of the 
liver  and  lead  to  portal  hypertension,  possibly 
complicated by portal vein thrombosis (Amitrano & 
Guardascione,  in  this  issue).  However,  the 
incidence  of  hepatocellular  carcinoma,    is  higher 
among  patients  with  viral  cirrhosis,  and  requires 
often  a  strict  follow-up  and  a  prompt  treatment, 
whether possible (Granito & Bolondi, in this issue). 
In  this  article,  we  describe  one  of  the  most 
interesting and debated arguments in matter of liver 
disease and cirrhosis, the alteration of haemostatic 
system  and  the  predisposition  to  hypo- and 
hypercoagulability. We will analyze the dichotomy 
between  tendency  to  bleeding  and  tendency  to 
thrombosis,  and  its  pathophysiologic aspects  in 
cirrhotic  patients,  reporting  perplexities  and 
certainties of a long lasting debate.
The Haemostatic System in Patients With Liver 
Cirrhosis: Bleeding  is  a common  and  well-know 
problem  in  clinical  management  of  cirrhotic 
patients. Several conditions, often associated, have 
been  recognized  to  predispose  to  a  major 
hemorrhagic  event.  The  principal  one  is  portal 
hypertension,  which  predispose  to  varices 
development,  portal  hypertensive  gastrophaty, 
splenomegaly  and  secondary  thrombocytopenia; 
nevertheless,  anticoagulant  treatment  or  excessive 
liquid  infusion  may  favor  bleeding,  directly  or 
through dilution of clotting factors. By the way, it is 
common  opinion  that  in  patients  with  a  severe 
coagulative defect, due to impaired liver function, 
bleeding occurs only in  the presence of anatomic 
lesions.  Recently, this widespread belief has been 
revised,  underlying  the  profound  modifications  in 
pro-coagulant  as  well  as  in  the  anti-coagulant 
pathway. Indeed, almost all the elements of clotting 
system  are  affected  by  liver  disease,  with  an 
unstable  haemostatic  balance  as  a  result.  Platelet 
count  is  often  reduced,  as  a  consequence  of 
hypersplenism,  less  frequently  for  defective 
production of thrombopoietin and growth factors, or 
the presence of anti-platelet antibodies, or folic acid 
deficiency,  or  drug  toxicity
9,10.  Moreover,  in  the 
cirrhotic patients the platelets seem to suffer a kind 
of  dysfunction,  probably  for  the  influence  of 
endothelial  inhibitory  products  (i.e.  nitroxyd  and 
prostacyclin),  increased  levels  of  von  Willebrand 
factor, alterations of GpIb protein, and tromboxane
A2  deficiency
11.  Thus,  in  cirrhotics  the  platelet 
dysfunction  seems  to  be  mostly  restricted  to  the 
adhesion to sub-endothelium,but further studies are 
needed to confirm these data
11-13.
Therefore, primary  haemostasis is  affected by 
altered platelet dysfunction, due to reduced platelet 
adhesion  and  to  endothelial  dysfunction; 
nevertheless,  the  ratio  between  low  and  high 
molecular weight subunits of von Willebrand factor 
is  reduced. This  is  due to  the  presence of higher 
levels  of  high  molecular  weight  subunits,  with  a 
capacity  of  adhesion  counteracting  the  platelet 
dysfunction
11. 
As regards secondary haemostasis, the process 
of  γ-carboxylation  of  factor  II,  VII,  IX  and  X 
production is impaired in the patients with chronic 
liver disease. Indeed, liver storage of vitamin K is 
poor  and,  in  case  of  cholestatic  disease,  its 
absorption is reduced. In contrast, factor VIII/von 
Willebrand  factor  ratio  is  always  increased
15. 
Moreover, fibrinogen levels appear quite stable in 
patients  with  stable  liver  disease,  but  they  are 
sensibly lower in advanced stages or in acute liver 
failure.  Dysfibrinogemia  and  decreased  levels  of 
factor V and XIII are common findings too. 
As previously discussed, the alteration of pro-
thrombotic  mechanism  coexists  with  decreased 
levels  of  natural  anticoagulant  factors,  such  as 
protein C and S, antithrombin and heparin cofactor 
II, all  synthesized by liver
16,17. At the  same time, 
fibrinolysis  may  be  altered  (Figure 1). 
Plasminogen,  α2-antiplasmin,  α2-macroglobulin, 
and  thrombin  activatable  fibrinolysis  inhibitor 
(TAFI)  levels  may  be  reduced  during  acute  or 
chronic  liver  disease,  while  tissue  plasminogen 
activator  (t-PA)  levels  are  usually  increased. 
Moreover, urokinase plasminogen activator (u-PA) 
and  its  receptor  are  increased  but,  during  the 
progression of liver disease, plasminogen activator 
inhibitor 1 (PAI-1) production becomes prominent, 
even if at a lower rate in respect to those of t-PA. 
Thus,  except  in  acute  liver  failure,  when  the 
increased  PAI-1  may  compromise  fibrinolytic 
activity,  the  whole  of    these  modifications 
predispose to hyperfibrinolysis.
Frequently,  laboratory  investigations  may 
suggest  a  disseminated  intravascular  coagulation 
(DIC),  but  a  relatively  stable  platelet  count,  highMedit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Figure 1. Schematic overview of the fibrinolytic system
levels  of  factor  VIII  and  a  weak  tendency  to 
thrombin generation make the haemostatic state of 
cirrhotics  different from DIC. The relative integrity 
of other organs confirms this opinion, even if signs 
of  microthrombosis  can  be  detected.  Thus,  this 
condition  has  been  defined  as  “accelerated 
intravascular coagulation and fibrinolysis” (AICF), 
because of the high tendency to fibrinolysis and the 
resemblance with DIC
18. The main feature of AICF 
is  formation  of  a  fibrin  clot  more  susceptible  to 
degradation by plasmin, due to high levels of t-PA, 
to  inadequate  release  of  PAI-1,  and  to  reduced 
synthesis  of  α2-antiplasmin.  Using  specific
laboratory assays, AICF can  be detected in  about 
30% of cirrhotics, more frequently in patients with 
advanced liver failure
18-22.
This complex system may also be perturbed, i.e. 
by  renal  insufficiency  or  bacterial  infections, 
providing an increased predisposition to bleeding
22-
24.
Liver  is  also  able  to  synthesize  some 
coagulation  inhibitors  and  to  clear  inactivated 
clotting factors and fibrinolytic enzymes. A study 
showed  in  rabbits  that  I
125 marked  thrombin  
aggregated  to  antithrombin  was  quickly  removed 
from circulation by liver
14, and a similar mechanism 
has  been  recognized  for  the  complex  heparin 
cofactor  II  – thrombin
26-28.  Apparently,  liver  has 
only one mechanism of uptake, which is based on a 
unique  receptor,  the  low  density  lipoprotein 
receptor  related  protein  (LRP);  probably, 
vitronectin  takes  part  to  the process
29.  It  is  also 
notable that  liver uptake works optimally only  in 
presence of the enzyme aggregated to its target, but 
not  in presence of the  native or clivated enzyme. 
This  mechanism  may  play  a  pivotal  role  in 
maintaining  a  normal  haemostasis,  by  removing 
from  circulation  activated  proteins.  In  addition, 
because t-PA degradation takes place into liver too, 
cirrhotic patients have increased t-PA levels, with 
some effects on fibrogenesis. Indeed, the system t-
PA-plasmin  is  involved  in  activation  of 
transforming  growth  factor-β (TGFβ),  a  pro-
fibrogenic  cytokine,  which  is  essential    in  the 
pathogenesis  of  liver  cirrhosis.  This  complex 
interaction  may  link  coagulation  impairment  of 
chronic liver disease and fibrosis progression, until 
cirrhosis  development.  Wanless  et  al.
30,31
demonstrated  that  microthrombi  are  frequently 
present within hepatic vessels of patients with liver 
cirrhosis  and  other  studies  showed  a  correlation 
between  inherited  thrombophilic  conditions  and 
severity  and  progression  of  liver  disease
32-35.
Moreover, HCV infected haemophilic patients seem 
to have a slower disease progression, supporting the 
hypothesis that a hypercoagulant state may heavily 
worsen the natural history of liver disease
36.Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Mechanisms underlying  this  strict  interaction 
are still unknown, but two different theories seem to 
be plausible: parenchymal extinction and activation 
of  stellate cells, which are  pericytes found in  the 
perisinusoidal  space. According  to  parenchymal 
extinction  hypotesis,  vascular  microthrombosis, 
triggered  by  necroinflammation,  may  cause  liver 
ischemia and infarction, with loss of hepatic tissue 
replaced by fibrotic tissue; cirrhosis will result from 
the  confluence  of  these  microfibrotic  areas. 
Alternatively,  thrombin  may  induce  fibrogenesis 
both  directly,  activating  specific  receptors  on 
stellate  cells,  or  indirectly,  stimulating  release  of 
platelet-derived growth factors (PDGF) by platelets 
and  promoting  post-translational  activation  of 
TGFβ,  an  important  mediator  of  fibrogenesis
37-40.  
Thus, an excessive thrombin production my lead to 
hepatic fibrogenesis and cirrhosis; it is notable that 
stellate cells activation is, probably, not distincted 
by parenchymal extinction, confirming the role of 
coagulation in liver fibrosis progression
41.
Finally,  fibrinolysis  is  also  affected  by  liver 
disease, since all proteins involved in fibrinolysis, 
except for tissue plasminogen activator (tPA) and 
plasminogen  activator  inhibitor  1  (PAI-1),  are 
synthesized in the liver
41.
In conclusion, cirrhotic patients seems to have a 
tendency  to  hyperfibrinolysis
43,  due  to  reduced 
levels  of    α2-antiplasmin,  histidine-rich 
glycoprotein and factor XIII
44-49; in contrast, t-PA 
levels  are  increased
15,51-56 and  those  of  PAI-1  are 
variable  in  each  patient
16,17,52. Recently,    a  great 
importance has been given to TAFI, an enzyme that 
inhibits fibrinolysis, postulating that its deficiency 
in cirrhotic patients may favor fibrinolytic pathway 
in  cirrhotic patients
57,58.  However,  this  theory  has 
not  been  fully  confirmed
59 Probably,  this  wide 
variability  depends  by  a  difference  in  laboratory 
assays.  However,  it  must  be  remembered  that 
infections  and  physiologic  stress  increase 
fibrinolytic activity through the release of tPA; also, 
ascitic  fluid  has  a  fibrinolytic  activity,  mostly 
related  to  its  reabsorption  in  systemic 
circulation
60,61.  Thus,  there  are  still  concerns 
regarding the real fibrinolytic capacity of cirrhotic 
patients;    laboratory  investigations  capable  to 
evaluate  global  pro  and  anti  fibrinolytic  activity, 
rather than any single component, are missing. In 
the  future,  further  studies  should  look  after  the 
validation of more reliable tests, to be employed in 
clinical practice.
Coagulation Tests in Liver Cirrhosis: Abnormal 
haemostatic tests and bleeding episodes are strictly
associated in patients with liver cirrhosis, and it is a 
widely accepted opinion that the former may be the 
cause  of  the  latter.  Therefore,  clinicians  use  to 
routinely  monitor  coagulation  parameters  and  to 
correct  any  diagnosed  alteration,  to  avoid  the 
occurrence of complications after procedure at risk 
of  bleeding  (i.e.  hepatic  biopsy).  As  previously 
discussed,  liver  plays  a  primary  role  in  the 
homeostasis of coagulative and fibrinolytic system; 
patients  affected  by  chronic  liver  disease  may 
benefit of this strict follow up to recognize early a 
possible  and  dangerous  dysregulation.  However, 
this  tendency  has  been  called  into  question, 
reassessing  the  value  of  tests  used  in  clinical 
practice in predicting the real risk of bleeding and 
the suitability of possible therapeutic strategies
56. It 
is well known that cirrhotic patients impairment in 
primary  haemostasis  is  imputable  to  platelet 
quantitative and qualitative defects. They could be 
recognized  by  specific  tests,  like  platelet  count, 
aggregometry  and  cytofluorimetry,  or  by 
measurement of cutaneous bleeding time, prolonged 
in about 40% of cirrhotics
62. However, whether this 
alteration  has  or  not  a  clinical  relevance  is  still 
questionable.  Some  authors  demonstrated  that  a 
prolonged bleeding time (more than 12 minutes) is 
associated  to  an  increased  risk  of  hemoglobin 
reduction,  after  liver  biopsy
63. Regarding  Von 
Willebrand  factor  dysfunction  present  in  chronic 
liver disease, some experimental tests have recently 
been  performed  in  condition  mimicking  in  vivo
blood  flow  circulation;  it  has  been  demonstrated 
that  higher  von  Willebrand  factor  levels  may 
compensate  functional defect. These  data  confirm 
that since a prolonged bleeding time is not due to a 
mild thrombocytopenia or to a thrombocytopathy, it 
may  be  of  scarce  utility  in  predicting  risk  of 
bleeding in cirrhotic patients. 
Liver cirrhosis is also characterized by reduced 
synthesis  of  the  most  part  of  clotting  factors, 
recognizable by measuring blood concentration of 
each of them or, indirectly, by testing prothrombin 
time (PT) and activated partial thromboplastin time 
(aPTT).  However,  commonly  PT  and  aPTT  are 
weakly related to bleeding after risky procedures in 
cirrhotic  patients.  International  normalized  ratio 
(INR), derived from PT standardization, is one of 
the parameters evaluated in MELD scoring system, 
and is used for prognostic assessment and thus in 
transplantation  to  ensure  organ  allocation. 
Interestingly, since INR is used to test coagulation 
in patients on oral anticoagulants, the international 
sensitivity  index  (ISI)  values  for  thromboplastin 
used  to  convert  PT  into  INR  derives  by  testing Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
plasmas from this kind of patients, a very different 
condition  from  liver  cirrhosis.  Therefore,  some 
authors reassessed INR values creating a different 
ISI  index,  using  plasma  from  cirrhotic  patients 
(instead of patients on oral anticoagulants) against 
the  WHO  international  standard  to  provide 
calibration
64.  As  a  result,  the  INR  obtained  with 
different  thromboplastins  were  not  significantly 
different in cirrhotic patients, in contrast to patients 
on oral anticoagulants. Since INR is an important 
parameter of MELD scoring system and may alter 
the  correct  evaluation  of  patients  prognosis, 
especially  those  candidates  for  transplantation,  it 
could  be  considered  whether manufacturers  of 
commercial  thromboplastins  and  point-of  care 
coagulation monitors should provide two ISI values, 
one of which valid for cirrhotic patients
64.
Probably,  PT  and  aPTT  are  inadequate  to 
investigate  coagulation  as  it  takes  place  in  vivo, 
especially in presence of complex alterations of the 
pro- and anticoagulant system, such as chronic liver 
disease.  Moreover,  natural  anticoagulants  have  to 
be  activated  to  gain  its  function.  In  vivo,    the 
activation of protein C is mediated by thrombin and 
its  endothelial  receptor  thrombomodulin. 
Antithrombin  too  has  to  be  activated  by 
glycosamminoglicanes,  like  heparansolfate, 
localized on endothelial surface. Therefore, in vitro 
samples  of  PT  and  aPTT  evaluation,  free  of 
thrombomodulin  and  glycosamminoglicanes,  can 
only  partially  evaluate  the  sole  function  of 
procoagulant factors, excluding thrombin inhibition 
by anticoagulant ones. In synthesis, these samples 
are inadequate to evaluate defects in anticoagulation 
or  the  global  mechanism  and  the  complex 
interactions between pro- and anticoagulants.
Recently,  haemostatic  blood  capacity  of 
cirrhotic  patients  has  been  compared  to  that  of 
healthy  subjects,  sampling  the  endogenous 
thrombin potential (ETP)
65,66.  It has been realized 
using  the  so  called  “thrombin generation  test”, 
which  is  performed  adding  to  plasma  poor  of  
platelet  a  small  quantity  of  recombinant  tissue 
factor  and  exogenous  phospholipids,  as  platelet 
substitutes, to trigger coagulation; thrombomodulin 
may  or  not  be  added  to  activate  protein  C.  The 
amount of generated thrombin is monitored using a 
fluorogenic  substrate.  Results  are  expressed  by  a 
curve, relating thrombin concentration to time; it is 
characterized  by  the  lag  phase,  the  peak  of 
thrombin, the time to peak, and the area under the 
curve, which is  called the ‘‘endogenous thrombin 
potential’’(Figure 2).  Tripodi et al.
21,68 showed that 
in  cirrhotic  patients  thrombin  generated  without 
addition of thrombomodulin was reduced, because 
of  the  reduced  hepatic  prothrombin  synthesis. 
However, in the presence of thrombomodulin, their 
thrombin  generation  test  was  similar  to  healthy 
subjects, confirming the existence of such a balance 
between  reduction  of  procoagulant  (prothrombin) 
and anticoagulant (protein C) factors. The principal 
limit of this study was the use of plasma poor in 
platelet,  differently  from  what  happens  in  vivo. 
Thus,  the  same  authors  performed  the  thrombin 
generation test using platelet-rich plasma
13; in the 
absence of thrombomodulin and with a standardized 
platelet count, cirrhotic patients generated a lower 
amount of thrombin in respect to controls. After the 
addition of thrombomodulin, this difference became 
inconsistent when platelet count was standardized, 
while,  if  the  real  patient  platelet  count  was 
considered, thrombin generation by cirrhotics was 
decreased.  In  particular,  the  amount  of  thrombin 
was the more scarce the lower was platelet count. 
According to these results, thrombin generation test 
seems, currently, the most accurate in sampling the 
whole  activity  of  pro- and  anticoagulant  factors, 
reproducing  a  system  very  close  to  in  vivo
conditions. However, even if this test may be useful 
in  the  future  to  predict  the  risk  of  bleeding  in 
cirrhotic patients, it cannot consider other factors, 
such  as  infections  and  renal  failure,  which  may 
influence in vivo haemostatic balance
67,68.
Predisposition  to  Bleeding  or  to  Thrombosis?
Haemostasis  in  cirrhotic  patients  is  the  result  of 
impairment in both pro and anticoagulant system, as 
previously  discussed.  This  balance  is  hard  to  be 
maintained,  sometimes  producing  bleeding, 
sometimes thrombosis and hypercoagulability. This 
condition  has  been  compared  to  a  “buffered” 
system,  in  which  pro-coagulant  tendency  is 
counterbalanced  by  coagulation  inhibitors  and 
negative  feedbacks
69.  In  healthy  subjects,  plasma 
concentration of clotting factors is widely above the 
“security  level”,  necessary  to  ensure  a  correct 
coagulation; for this reason, physiologic, pathologic 
and  stressful  events  have  limited  effects  on 
haemostatic  system,  rarely  determining  bleeding. 
Similarly, patients affected by chronic liver disease 
may, in stable clinical conditions, maintain a normal 
haemostatic  capacity,  since  the  synthesis  of  only 
that  part  of  clotting  factors  which  exceeds 
“standard” level is reduced
21,70. By the way, when 
this  equilibrium  is  perturbed  by  extrinsic  factors, 
such  as  infections,  frequently  the  result  is 
occurrence  of  bleeding  or  development  of 
thrombosis
25.Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Figure 2
68. Thrombin generation curve (thrombogram). The endogenous thrombinic potential (ETP) corresponds to the area under 
the curve.  
Hypercoagulability and Liver Cirrhosis: Risk of 
Thrombosis:  Generally,  a  hypercoagulable  state 
may  manifest  in  both  macrovascular  or 
microvascular  system.  Microvascular  thrombotic 
disease is often difficult to recognize and, for this 
reason, underdiagnosed. For cirrhotic patients, the 
principal  trigger  may  be  the  presence  of  either  a 
transient  or  chronic  disequilibrium  in  haemostatic 
system, i.e. caused by infections, which leads to a 
loss of endothelial barrier function and activation of 
coagulation  cascade  with  consequent  thrombin 
generation.  Moreover,  vasoconstrictive  and 
proliferative signals may favor the development of a 
plexogenic  arteriopathy
71.  We  already  discussed 
how  this  mechanism  may  promote  hepatic 
fibrogenesis  and  fibrosis  progression  to  cirrhosis, 
influencing the natural time course of liver disease, 
but this microvascular thrombotic lesions are also 
involved  in  the  pathogenesis  of  liver  disease 
complications.  Portopulmonary  hypertension, 
alteration  of vascular permeability  in  spontaneous 
bacterial peritonitis and renal dysfunction in type 2 
hepatorenal  syndrome  probably  recognize  the 
microvascular  disease  as  a  common  etiology
72,74. 
Macrovascular thrombotic disease, instead, is more 
easily recognizable in cirrhotic patients, expressing 
with  deep  non-splanchnic  venous  thrombosis, 
pulmonary  embolism  and,  frequently,  portal  vein 
thrombosis (PVT)
75.
PVT  has  often  a  multifactorial  etiology,  in 
general population. A practical distinction between 
local  and  systemic  conditions  may  be  useful  to 
recognize patients at high risk of PVT development 
(Table 1 and 2)
76. Liver cirrhosis holds a central 
position  among  all  other  causes  of  PVT 
development,  together  with  local  inflammation  or 
tumors
77,78. PVT prevalence in cirrhotic patients is 
reported  to  be  0.6-16%,  the  highest  among 
candidates  for  liver  transplantation  and  of  about 
6.5% in patients with hepatocellular carcinoma at 
the  moment  of  diagnosis
76.  It  is  notable  how,  in 
patients  affected  by  chronic  liver  disease, 
inflammatory  conditions  or  hepatocellular 
carcinoma may often coexist, contributing to PVT 
development.  Furthermore,  in  presence  of  hepatic 
tumor, PVT incidence rises to 10-40% in cirrhotic 
patients
79.  Porto-systemic  shunting,  liver 
transplantation, ablative therapy for  HCC or  intra 
abdominal  fine  needle  aspiration  may  represent 
other triggers for PVT development
80. Apart from 
local  risk  factors,  systemic  disorders,  such  has, 
myeloproliferative  neoplasms  (MPN)  and 
prothrombotic  conditions,  were  reported  to  be 
responsible  of  about  40-60%  of  PVT  in  general 
population
77,81.  Factor  V  Leiden  and  protein  C 
deficiency  seems  to  be  the  most  frequently 
involved; however, the role of protein C and protein 
S deficiency  is  difficult  to  be  evaluated  during 
anticoagulant therapy and is still to be confirmed
82. Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Increased levels of factor VIII seems to be related to 
an increased risk of PVT development too
83-85; in 
particular, cirrhotic patients with plasmatic levels of 
factor VIII beyond the 66
th percentile (129 IU/dL) 
are reported to have a 6-fold greater risk of PVT 
development
86.  However,  the  presence  of  a 
congenital prothrombotic disorder has always to be 
taken  in  account,  even  in  cirrhotic  patients. 
According to literature, prothrombin gene mutation 
seems  to  be  the  most  frequent  thrombophilic
disorder among cirrhotics with PVT
87-91. 
Table 1
76. Most frequent local risk factors for PVT   
Amitrano et al. also showed that prothrombin 
G20210A  mutation  is  strongly  related  to  PVT
development in cirrhotic patients, even in absence 
of  hepatocellular  carcinoma
92.  In  contrast,  the 
question  of  anticardiolipin  antibodies  positivity  is 
still  discussed,  since,  although  it  is  a  frequent 
finding of laboratory investigations, it is influenced 
by  infections  and  often  considered  as  an  indirect 
manifestation of liver  damage
92-96. This  and other 
doubts  are  supported  by  the  low  estimated 
prevalence  of  genetic  prothrombotic  conditions 
among  cirrhotic  patients.  Moreover,  it  is  always 
hard to distinguish between hereditary or acquired 
deficiency of coagulation proteins, because of their 
plasmatic  concentration  is  influenced  by  liver 
function  impairment
97. For  all  these  reasons,  to 
discover  a  potential  genetic  alteration  in  these 
subjects is often difficult and may lead to diagnostic 
mistakes
98. Several  studies  tried  to  provide  an 
alternative  method,  cheaper  and  easier  to  be 
performed  than  genetic  screening.  Some  authors 
proposed the ratio of PS or PC or AT to [(factor II + 
factor  X)/2]  could  furnish  a  sufficiently  reliable 
overview  of  patient  haemostatic  alterations.    A 
genetic thrombophilic condition is highly probable 
in  case  of  a  result  lower  than  70%
80. Finally, 
familial  screening  is  the  more  reliable  tool  to 
confirm  the  inborn  nature  of  deficiency;  indeed, 
such defects are inherited in a dominant manner, so 
their  presence  is  proven  by  detecting  the  natural 
anticoagulant deficiency in at least one first-degree 
sibling. On the hand, the finding of normal levels of 
natural  anticoagulants  in  both  parents  renders 
diagnosis unlikely. 
Table 2
76. Frequent systemic risk factors for PVT
MPN represent another common cause of PVT 
development in the general population
87,99,100. In the 
Western  Countries,  58%  of  idiopathic  PVTs  are 
associated to a latent MPN
101,102. A simple method 
to investigate an underlying predisposition to MPN 
in  PVT  patients  is  screening  the  V617F  point 
mutation  in  the  gene  encoding  tyrosine-protein 
kinase  JAK2
103-107.  Recently,  it  has  been  reported 
the presence of the JAK2 V617F gene mutation in 
about  17-35%  of  PVT  patients  without  a  known 
underlying  disease
108-110;  however  the  prevalence 
among cirrhotic PVT patients is actually unknown.
In a recent  study, Zocco et  al.
111 showed that 
portal flow velocity is strongly predictive of PVT 
development. In particular, 47.8% of patients with a 
portal  flow  velocity  lower  than  15  cm/sec  at 
Doppler Ultrasound  developed PVT, in contrast to 
only 2% of those with a measured velocity above 15 
cm/sec. Probably, the reduced removal of thrombin 
LOCAL RISK FACTORS FOR PVT (70%)
Cancer
 Any abdominal organ
Focal inflammatory lesions
 Neonatal omphalitis, ombilical vein catheterization
 Diverticulitis, Appendicitis
 Pancreatitis
 Duodenal ulcer
 Cholecystitis
 Tuberculous lymphadenitis
 Crohn’s disease, Ulcerative colitis
 Cytomegalovirus hepatitis
Injury to the portal venous system
 Splenectomy
 Colectomy, Gastrectomy
 Cholecystectomy
 Liver transplantation
 Abdominal trauma
 Surgical portosystemic shunting, TIPS, 
 Iatrogenic (fine needle aspiration of abdominal 
masses etc.)
Cirrhosis
 Preserved liver function with precipitating factors 
(splenectomy, surgical portosystemic shunting, 
TIPS dysfunction, thrombophilia)
 Advanced  disease  in  the  absence  of  obvious 
precipitating factors
SYSTEMIC RISK FACTORS FOR PVT (30%)
Inherited:
 Factor V Leiden mutation
 Factor II (prothrombin) mutation
 Protein C deficiency
 Protein S deficiency
 Antithrombin deficiency
Acquired:
 Myeloproliferative disorder
 Antiphospholipid syndrome
 Paroxysmal nocturnal hemoglobinuria
 Oral contraceptives
 Pregnancy or puerperium
 Hyperhomocysteinemia
 MalignancyMedit J Hemat Infect Dis 2009; 1(3); Open Journal System 
due  to  blood  stagnation,  together  with  reduced 
levels  of  circulating  anticoagulants,  may  produce 
the  local  conditions  predisposing  to  PVT.  This 
study  opens  new  interesting  perspectives, 
considering  also  that  evaluation  of  portal  flow 
velocity  needs  only a  Doppler  Ultrasound 
measurement, in clinical practice. However, further 
studies are necessary to confirm these data and to 
identify other factors helpful to recognize patients at 
high risk of PVT development
112.
Risk  of  Bleding  and  Liver  Cirrhosis:  Bleeding 
manifestations  are  usually  common  during  the 
natural  course  of  chronic  liver  disease
42,  most  of 
them not  life  threatening (i.e.  bruising, petechiae, 
purpura,  nose  bleeds,  and  bleeding  after  dental 
extractions).  The  contribution  of  a  defective 
haemostasis  has  been  already  evaluated  in  this 
review
113,114;  however,  it  is  certain  that  the 
increasing  in  portal  venous  pressure  is  the  most 
important  trigger  to  bleeding.  This  hemodynamic 
alteration  is  not  only  confined  to  splanchnic 
vascular  bed  but,  rather,  it  is  a  complex  clinical 
syndrome affecting several systems and organs
115. 
Hypervolemia,  increased  cardiac  index, 
hypotension, decreased systemic vascular resistance 
and renal vasoconstriction configure the so called 
“effective  hypovolemia”,  which  is  part  of  the 
hyperkinetic  syndrome  often  associated  to  portal 
hypertension;  it  is  on  the  basis  of  ascites, 
hepatorenal  syndrome,  cirrhotic  cardiomyopathy, 
hepatopulmonary  syndrome  and  portopulmonary 
hypertension development and also responsible for 
hypersplenism-related  pancytopenia  and  skin 
alterations  (warm  skin,  palmar  erythema,  spider 
angiomas)
116-121.  However,  bleeding  from 
gastrointestinal  tract  is  the  most  frightening 
manifestation  of  portal  hypertension.  Splanchnic 
vasodilation,  decreased  responsiveness  to
vasoconstrictors, neo-angiogenesis and formation of 
portal-systemic  collaterals  (gastroesophageal 
varices,  portal  hypertensive  gastropathy  and 
colopathy)  are  common  findings  in  cirrhotic 
patients  with  portal  venous  pressure  above  10 
mmHg
129-131.  It  is  extimated  that  about  5-10%  of 
cirrhotic patients per year develop new varices
125-
129,  while  30-40%  of  them  present  varices  at  the 
time  of  diagnosis
123,128,129.  Variceal  progression  is 
associated to decompensation, high MELD or Child 
Pugh  score,  alcoholic  etiology  of  cirrhosis  and 
presence of red wale signs
130-131. Bleeding incidence 
is reported about 4% per year, 15% in patients with 
medium-large varices; other risk factors are Child 
Pugh class, presence of red marks, hepatic venous 
pressure  gradient  (HVPG)  above  12 
mmHg
129,131,133,134. As previously discussed, the role 
of  cirrhotic  coagulopathy  in  favoring  variceal 
bleeding is questionable. However, the more severe 
is liver dysfunction the more difficult is to control 
bleeding,  and  often  more  prone  to  recur
142,143. 
Alterations in  primary  and secondary  haemostasis 
typical  of  advanced  liver  disease  has  been 
postulated as the principal explication; by the way, 
as  we  previously  discussed  in  this  article,  the 
complex  balance  in  cirrhotics  haemostatic  system 
does  not  necessarily    predispose  to  bleeding. 
Otherwise, fybrinolitic activity has been recognized 
as  a  good  predictor  of  gastrointestinal 
hemorrhage
137,138.  Probably,  in  the  course  of 
bleeding, a hyperfibrinolytic state compromises clot 
stabilization  and  favor its  disruption.  Moreover, 
coagulation may be delayed for the lower levels of 
clotting  factors  due  to  a  continuous  consumption 
and platelet function seems to be impaired too
141-142. 
Some  authors  reported  a  correlation  between 
fibrinogen degradation products or D-dimer levels, 
t-PA activity and the risk of bleeding, but pointing 
out  a  relativity  low  specificity;  thus  their  use  in 
clinical practice should be careful and evaluated on 
a case by case basis
143,144. 
Conclusions:  Viral  hepatitis  is  a  major  health
problem  worldwide,  being  the  principal  cause  of 
chronic  liver  disease,  cirrhosis  and  hepatocellular 
carcinoma.  Once  cirrhosis  develops,  patients  are 
subjected to all complications derived from hepatic 
dysfunction  and  development  of  portal 
hypertension.
Among  all  these  complications,  haemostatic 
alterations have been considered for long time the 
principal  cause  of  bleeding  in  cirrhotic  patients. 
However, the scarce correlation between episodes 
of bleeding and alterations in coagulation test have 
changed  this  opinion.  The  balance  between  hypo 
and hypercoagulation, maintained by deficiency of 
both pro- and anticoagulant factors and fibrinolytic 
system,  may  explain  why  these  patients  are  not 
protected  by  either  the  risk  of  bleeding  or  of 
thrombosis development.
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